GlassScriptPhysician profile
Elliott A Schulman
NPI 1225000698
$66,760.07
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $21K · 2021: $1,369 · 2022: $868 · 2023: $18.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27,105.28 | 2019-2020 | |
| Amgen INC. | $18,435.25 | 2019-2021 | |
| Allergan, INC. | $7,820.62 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $7,711.75 | 2019-2020 | |
| Lundbeck LLC | $2,762.50 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $940.00 | 2021-2022 | |
| Ucb, INC. | $259.13 | 2019 | |
| Supernus Pharmaceuticals, INC. | $250.33 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $239.23 | 2019-2020 | |
| Merz North America, INC. | $166.06 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $128.39 | 2019-2020 | |
| Boston Scientific Corporation | $96.73 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $92.21 | 2019-2021 | |
| Bausch Health US, LLC | $91.75 | 2019-2020 | |
| Genzyme Corporation | $83.14 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Promius Pharma LLC | $78.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.31 | 2019 | |
| Nevro Corp. | $58.86 | 2019 | |
| Zyla Life Sciences, INC. | $46.43 | 2019 | |
| Acadia Pharmaceuticals INC | $36.42 | 2019 | |
| Abbvie INC. | $33.85 | 2021-2023 | Botox |
| Mdd US Operations, LLC | $30.85 | 2020 | |
| Alexion Pharmaceuticals, INC. | $29.78 | 2019 | |
| Si-Bone, INC. | $22.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.90 | 2020 | |
| Eisai INC. | $21.90 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.80 | 2019 | |
| Abbott Laboratories | $20.52 | 2019 | |
| Adamas Pharmaceuticals, INC. | $20.17 | 2019 | |
| Csl Behring | $18.77 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.62 | 2019 | |
| Tanabe Pharma America, INC. | $14.99 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.41 | 2020 | |
| Akcea Therapeutics, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliott Schulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.